I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 ...
Uliledlimab shows safety and efficacy in NSCLC, with CD73 expression linked to clinical response. A Phase 3 study in NSCLC is planned for 2023. I-Mab to host an investor call on May 27, 2022, to discuss findings.
Related Clinical Trials
Reference News
Uliledlimab shows safety and efficacy in NSCLC, with CD73 expression linked to clinical response. A Phase 3 study in NSCLC is planned for 2023. I-Mab to host an investor call on May 27, 2022, to discuss findings.
I-Mab announces a conference call on May 27th to present phase 2 trial data for uliledlimab, a CD73 antibody, and its global development plan. Uliledlimab targets tumor growth by inhibiting adenosine production, enhancing anti-tumor responses alongside checkpoint therapies. I-Mab focuses on innovative biologics for immuno-oncology.